Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aquestive Therapeutics, Inc. (AQST) vs Alpha Teknova, Inc. (TKNO)

Aquestive Therapeutics, Inc. and Alpha Teknova, Inc. are both Drug Manufacturers Specialty & Generic companies. Aquestive Therapeutics, Inc. is the larger, with a market value of $605.0M against $498.8M — 1.2× the size. Aquestive Therapeutics, Inc. grew revenue faster over the last twelve months: 22.6% against 12.3%. Alpha Teknova, Inc. has the higher net margin (−38.4% vs −144.6%) and the lower return on invested capital (−16.9% vs 0.00%). Across the 17 metrics below, Alpha Teknova, Inc. leads on 9 and Aquestive Therapeutics, Inc. on 8.

Valuation

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 10.82 11.45 2.25
P/B n/m 7.99 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 9.93 11.45 2.56
Earnings yield (13.89%) (3.32%) (2.99%)
Free cash flow yield (7.85%) (1.47%) 0.00%

Profitability

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
Gross margin 67.04% 34.60% 53.94%
Operating margin (97.52%) (36.19%) 0.00%
Net margin (144.63%) (38.37%) 0.00%
Free cash flow margin (84.95%) (16.83%) 0.00%
Return on equity 121.12% (24.19%) (0.40%)
Return on assets (69.29%) (16.25%) (3.32%)
Return on invested capital 0.00% (16.93%) 0.00%

Growth

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 22.56% 12.27% 10.01%
EPS growth (last fiscal year) (52.94%) 43.86% —
Revenue growth, 5-year CAGR (0.58%) 5.30% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
Debt to equity (0.90) 0.21 0.05
Current ratio 7.19 4.49 2.31
Net debt to EBITDA 1.57 0.75 0.85

Dividend

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AQST TKNO Drug Manufacturers Specialty & Generic median
Market cap 604.97m 498.76m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack